



ACN 010 126 708

ASX Release
17th August 2016

R&D Tax Incentive Refund Receipt

Adelaide, 17th August 2016: Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) announces today that it has received a Research and Development Tax Incentive refund from the Australian Taxation Office of \$278,104. This is in keeping with the Company’s previous advice to the market.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9348
michelle.fraser@rhsc.com.au

Dr David Brookes
Chairman
Tel: (+61 8) 8152 9383
david.brookes@rhsc.com.au

About Reproductive Health Science

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, with over 10 years of technical experience in the field. EmbryoCollect™ is the Company’s lead product designed to increase the chance of a successful IVF cycle by selecting the most viable embryos for transfer by screening for aneuploidy. This is known as Preimplantation Genetic Screening (PGS). RHS is now launching its second product, DOPlify™ for whole genome amplification of single or small numbers of cells. DOPlify™ is applicable to the global Next Generation Sequencing market.

Reproductive Health Science Ltd.

ACN 010 126 708
ASX: RHS

Issued Capital

59 million shares
13.1 million options

Registered Office

Level One, BioSA Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9380
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Directors

Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Dr Michelle Fraser (CEO)

Finance Officer

& Company Secretary
Raymond Ridge